Latest News
Events
Press Releases
Curetis raises EUR 12.5 million in Series B round led by new investor HBM Partners
Co-investment of all current institutional investors as well as several private investors and management
Company now has access to over EUR 20 million in cash for the next phase of commercial and operational growth
Curetis to Present Clinical Unyvero™ Data at ECCMID 2013 in Berlin
Company to host medical symposium on molecular antibiotic resistance testing in standard care
Curetis AG Strengthens Commercial Team and Expands Distribution Network
Appointment of Helmut Hlibert as Head of Business Development
Distribution Agreement with ELITech in Belgium and Luxembourg
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples
Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyvero™ Cartridge Plastics Parts
German family firm ‘Scholz-HTIK – High Tech in Kunststoff’ has been selected by Curetis based on systematic benchmarking process
Curetis AG stärkt Sales- und Marketingteam und erweitert Vertriebsnetz
Ernennung von Helmut Hilbert als Head of Business Development
Vertriebsvereinbarung mit ELITech in Belgien und Luxemburg
Curetis Completes Enrollment for its EU Trial As Planned
Prospective multi-center trial enrolls 800 patient samples
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
Partners to start registration process and market launch in Russia
Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands
Partners prepare market launch and clinical evaluation project
Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge
Joint development of cartridge for orthopaedics, wound and surgery infections
Curetis AG to Present Its Unyvero™ Solution at DGHM Conference
Company hosts medical symposium on bacterial pneumonia and antibiotic resistance at the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM)
Curetis AG and Cempra, Inc. Collaborate on the Detection of Community-Acquired Bacterial Pneumonia Pathogens
Cempra to use Curetis’ Unyvero™ solution in its Phase III trial of its antibiotic solithromycin (CEM-101)
Curetis AG Signs Distribution Deal in Middle East with ATC
Kuwait Ministry of Health clears Unyvero™ Solution for clinical evaluation
Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization
Successful completion of performance evaluation study;
CE Mark for Unyvero™ instrument system and pneumonia application
Curetis AG to Present Its Unyvero™ System for Pneumonia Diagnostics
Demonstration supported by symposium on bacterial pneumonia
and emerging antibiotic resistance at the 22nd European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID)
Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics
Expected CE-marking and launch in Europe in 2012
Curetis AG Appoints Dr. Klaus Brinkmann as Director of Sales
Preparation of CE-marking and product launch in Europe in 2012.
read more
Curetis AG attracts Forbion and Roche as new investors
Series A financing round expanded to €34.1 million
read more
Curetis AG Opens Unyvero™ Cartridge Production Facility
Manufacturing capacity scalable to up to 1 Mio. cartridges per year.
read more
Curetis AG successfully increases Series A financing
round to EUR 24.5 million
Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series
read more
Curetis AG and its Partners obtain Additional € 0.5 Million Funding under German Federal Innovation Grant Program
Federal funding for joint R&D project of Curetis AG (Holzgerlingen, Germany), Polytechnic Schmalkalden (Germany) and Contexo GmbH (Winterbach, Germany) towards mass production optimization of consumables for innovative infectious disease diagnostics.
read more
Curetis appoints Oliver Schacht as CEO
Curetis AG announces the appointment of Oliver Schacht (current CFO Epigenomics AG / CEO Epigenomics, Inc.) as CEO, effective 1st April 2011.
read more
Curetis completes Supervisory Board and announces new CFO
Curetis AG announces the election of Oliver Schacht (Epigenomics AG) as new Supervisory Board Member. In addition, Anne Burger (MedVenture Partners) has been appointed as new CFO.
read more
Curetis AG increases Series A Financing to € 20 Million and receives ISO 13485 Certification
With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through the market entry.
read more
Curetis AG: Development of products to effectively diagnose severe infections is secured until market entry.
A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.
read more
This solution will save many lives
The joint project between the Institute of Medical Microbiology and Hygiene in Tübingen (Germany), the Natural and Medical Sciences Institute (NMI), Reutlingen (Germany) and start-up Curetis AG aims at the development of new diagnostic solutions to detect hospital-acquired infections.
© Curetis AG 2013